Second, social media has become a parallel infrastructure for obesity care, filling gaps in counselling, reassurance and realworld tips
Your healthcare team may submit a report to the MHRA Yellow Card Scheme, which collects data on pregnancy outcomes after exposure to GLP-1 medicines
Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease
Most find these effects to be manageable and a minor trade-off for the benefits
If youre looking to start making positive changes to your health now, waiting years for an unreleased drug is a less preferable option when theres a highly effective option sitting on the shelf today
That approach fails because your digestive system is operating under entirely different rules now